KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Merck (MRK) Change in Receivables (2009)

Merck (MRK) reported Change in Receivables of $14.0 million for Q4 2009, down 88.71% on a QoQ basis from $124.0 million in Q3 2009.

Merck (MRK) has 1 years of Change in Receivables data on file, last reported at $14.0 million in Q4 2009.

  • Quarterly Change in Receivables changed N/A year-over-year to $14.0 million in Q4 2009, while the trailing twelve-month figure through Dec 2009 was $1.4 billion (changed N/A YoY) and the FY2025 annual result came in at $1.1 billion, up 346.72% from the prior year.
  • Change in Receivables declined to $14.0 million in Q4 2009 per MRK's latest filing, from $124.0 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $124.0 million in Q3 2009 and bottomed at $14.0 million in Q4 2009.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -504.00 Mn
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn -
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 595.00 Mn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -87.00 Mn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn -413.00 Mn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn -134.00 Mn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -1.69 Bn
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2009 14.00 Mn
Dec 31, 2009 14.00 Mn
Sep 30, 2009 124.00 Mn
Sep 30, 2009 124.00 Mn